Pictet Asset Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$174K Buy
21,342
+5,051
+31% +$45.8K ﹤0.01% 1964
2025
Q4
$109K Hold
16,291
﹤0.01% 2010
2025
Q3
$141K Hold
16,291
﹤0.01% 1943
2025
Q2
$103K Hold
16,291
﹤0.01% 1934
2025
Q1
$104K Hold
16,291
﹤0.01% 1923
2024
Q4
$131K Hold
16,291
﹤0.01% 1939
2024
Q3
$206K Hold
16,291
﹤0.01% 1799
2024
Q2
$206K Buy
16,291
+5,969
+58% +$60.1K ﹤0.01% 1743
2024
Q1
$49.3K Hold
10,322
﹤0.01% 1941
2023
Q4
$49.5K Hold
10,322
﹤0.01% 1936
2023
Q3
$74.7K Buy
+10,322
New +$82.5K ﹤0.01% 1872

Other funds holding NVAX

Pictet Asset Management's NVAX Position: Q1 2026 in Review

Pictet Asset Management increased its Novavax (NVAX) stake by 31% in Q1 2026, buying an estimated $45.8K and bringing the position to 21,342 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Pictet Asset Management first reported a position in NVAX in Q3 2023 and has held it in 11 quarters since. The position peaked at $206K in Q2 2024. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Pictet Asset Management held 21,342 shares of Novavax worth $174K as of Q1 2026.
  • Pictet Asset Management bought 5,051 Novavax shares in Q1 2026, an estimated $45.8K.
  • Novavax made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1964 holding.
  • Pictet Asset Management first reported a position in Novavax in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Novavax position peaked at $206K in Q2 2024.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.